| Avapritinib | hsa00220 | Arginine biosynthesis | 3.83E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | |
| Avapritinib | hsa00230 | Purine metabolism | 4.93E-02 | 1 | P21589 | NT5E | More | |
| Avapritinib | hsa00240 | Pyrimidine metabolism | 1.81E-02 | 1 | P21589 | NT5E | More | |
| Avapritinib | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2.03E-02 | 1 | P35557 | GCK | More | |
| Avapritinib | hsa00630 | Glyoxylate and dicarboxylate metabolism | 5.34E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
| Avapritinib | hsa00640 | Propanoate metabolism | 3.83E-02 | 2 | Q02252, Q9P2R7 | ALDH6A1, SUCLA2 | More | |
| Avapritinib | hsa00730 | Thiamine metabolism | 1.15E-03 | 2 | Q9Y6K8, P24666 | AK5, ACP1 | More | |
| Avapritinib | hsa00740 | Riboflavin metabolism | 2.80E-03 | 2 | P30043, P24666 | BLVRB, ACP1 | More | |
| Avapritinib | hsa00760 | Nicotinate and nicotinamide metabolism | 9.09E-03 | 1 | P21589 | NT5E | More | |
| Avapritinib | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | |
| Avapritinib | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Avapritinib | hsa02010 | ABC transporters | 4.48E-02 | 1 | Q8IZY2 | ABCA7 | More | |
| Avapritinib | hsa03013 | RNA transport | 3.94E-03 | 4 | O14893, Q14240, Q9BZI7, Q06787 | GEMIN2, EIF4A2, UPF3B, FMR1 | More | |
| Avapritinib | hsa03015 | mRNA surveillance pathway | 4.81E-02 | 2 | Q9BZI7, O94913 | UPF3B, PCF11 | More | |
| Avapritinib | hsa03040 | Spliceosome | 4.19E-02 | 5 | Q14562, O60508, P08579, Q01130, O43447 | DHX8, CDC40, SNRPB2, SFRS2, PPIH | More | |
| Avapritinib | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | |
| Avapritinib | hsa03460 | Fanconi anemia pathway | 2.71E-02 | 1 | O94782 | USP1 | More | |
| Avapritinib | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | |
| Avapritinib | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.32E-02 | 6 | P09341, P25024, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | |
| Avapritinib | hsa04062 | Chemokine signaling pathway | 6.73E-03 | 9 | P25024, P09341, P47992, Q9UBD3, P07948, P63218, P50151, P43250, Q08881 | CXCR1, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, GRK6, ITK | More | |
| Avapritinib | hsa04064 | NF-kappa B signaling pathway | 7.24E-03 | 8 | O00463, P14778, Q04759, P07948, P06239, P24522, P09341, Q06643 | TRAF5, IL1R1, PRKCQ, LYN, LCK, GADD45A, CXCL1, LTB | More | |
| Avapritinib | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | |
| Avapritinib | hsa04217 | Necroptosis | 7.34E-03 | 5 | P01568, Q13546, P07384, Q6FI13, P10415 | IFNA21, RIPK1, CAPN1, H2AC18; H2AC19, BCL2 | More | |
| Avapritinib | hsa04270 | Vascular smooth muscle contraction | 2.89E-02 | 2 | P35579, P35318 | MYH9, ADM | More | |
| Avapritinib | hsa04610 | Complement and coagulation cascades | 1.91E-03 | 1 | P0C0L4 | C4A | More | |
| Avapritinib | hsa04612 | Antigen processing and presentation | 1.75E-02 | 6 | P13765, P01730, P26715, P26717, Q13241, P01732 | HLA-DOB, CD4, KLRC1, KLRC2, KLRD1, CD8A | More | |
| Avapritinib | hsa04623 | Cytosolic DNA-sensing pathway | 7.69E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
| Avapritinib | hsa04640 | Hematopoietic cell lineage | 3.30E-05 | 11 | P13612, P14778, P27930, P25063, P07766, P09693, P01732, P01730, P06127, P09564, P13765 | ITGA4, IL1R1, IL1R2, CD24, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB | More | |
| Avapritinib | hsa04650 | Natural killer cell mediated cytotoxicity | 3.08E-03 | 8 | P06239, O60880, P20963, Q13241, P26718, O14931, P26717, P26715 | LCK, SH2D1A, CD247, KLRD1, KLRK1, NCR3, KLRC2, KLRC1 | More | |
| Avapritinib | hsa04658 | Th1 and Th2 cell differentiation | 2.44E-07 | 11 | Q04759, P07766, P20963, P09693, P01730, P06239, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, CD4, LCK, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | |
| Avapritinib | hsa04659 | Th17 cell differentiation | 4.63E-06 | 11 | Q04759, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | |
| Avapritinib | hsa04660 | T cell receptor signaling pathway | 8.91E-04 | 9 | Q04759, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239 | PRKCQ, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK | More | |
| Avapritinib | hsa04662 | B cell receptor signaling pathway | 1.49E-03 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | |
| Avapritinib | hsa04664 | Fc epsilon RI signaling pathway | 7.95E-04 | 5 | P42338, Q9UQC2, P07948, P09917, P20292 | PIK3CB, GAB2, LYN, ALOX5, ALOX5AP | More | |
| Avapritinib | hsa04724 | Glutamatergic synapse | 5.94E-03 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | |
| Avapritinib | hsa04725 | Cholinergic synapse | 4.10E-02 | 3 | P63218, P50151, P42338 | GNG5, GNG10, PIK3CB | More | |
| Avapritinib | hsa04727 | GABAergic synapse | 1.63E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | |
| Avapritinib | hsa04926 | Relaxin signaling pathway | 5.70E-03 | 5 | P42338, P63218, P50151, P49767, P49407 | PIK3CB, GNG5, GNG10, VEGFC, ARRB1 | More | |
| Avapritinib | hsa04929 | GnRH secretion | 4.62E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | |
| Avapritinib | hsa04950 | Maturity onset diabetes of the young | 2.03E-02 | 1 | P35557 | GCK | More | |
| Avapritinib | hsa04962 | Vasopressin-regulated water reabsorption | 7.22E-03 | 2 | P52566, P62491 | ARHGDIB, RAB11A | More | |
| Avapritinib | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | |
| Avapritinib | hsa04966 | Collecting duct acid secretion | 4.48E-02 | 1 | P00918 | CA2 | More | |
| Avapritinib | hsa05034 | Alcoholism | 3.30E-02 | 2 | Q96RR4, P84243 | CAMKK2, H3F3A | More | |
| Avapritinib | hsa05133 | Pertussis | 3.51E-02 | 1 | P0C0L4 | C4A | More | |
| Avapritinib | hsa05146 | Amoebiasis | 9.73E-03 | 6 | P09341, P14778, P27930, P05089, P12814, P08311 | CXCL1, IL1R1, IL1R2, ARG1, ACTN1, CTSG | More | |
| Avapritinib | hsa05150 | Staphylococcus aureus infection | 1.16E-03 | 6 | P0C0L4, P13646, Q14532, P59665, P59666, P49913 | C4A, KRT13, KRT32, DEFA1; DEFA1B, DEFA3, CAMP | More | |
| Avapritinib | hsa05168 | Herpes simplex virus 1 infection | 4.79E-02 | 8 | P25963, Q07955, Q01130, Q9Y2A4, P51522, P17038, P52738, O75820 | NFKBIA, SFRS1, SFRS2, ZNF443, ZNF83, ZNF43, ZNF140, ZNF189 | More | |
| Avapritinib | hsa05169 | Epstein-Barr virus infection | 5.94E-04 | 12 | P13765, P01106, Q13547, O00463, P42338, P07948, Q13761, P24522, O75293, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, PIK3CB, LYN, RUNX3, GADD45A, GADD45B, CD3E, CD3G, CD247 | More | |
| Avapritinib | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 9.73E-03 | 6 | P07766, P20963, P09693, P06239, Q04759, P01730 | CD3E, CD247, CD3G, LCK, PRKCQ, CD4 | More | |
| Avapritinib | hsa05332 | Graft-versus-host disease | 3.93E-02 | 3 | P13765, P26715, Q13241 | HLA-DOB, KLRC1, KLRD1 | More | |
| Avapritinib | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | |
| Avapritinib | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.48E-02 | 1 | P54284 | CACNB3 | More | |
| Avapritinib | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | |
